Mga Batayang Estadistika
| LEI | 529900MTJPDPE4MHJ122 |
| CIK | 1434265 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Genmab A/S - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 13, 2025 |
Articles of Association Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) (Unauthorized English translation) (August 12, 2025) Articles of Association of Genmab A/S (CVR-nr. |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal execut |
|
| August 12, 2025 |
Exhibit 99.1 Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; August 12, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 4,563 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subs |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal execut |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal execut |
|
| August 7, 2025 |
Exhibit 99.1 Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Company Announcement COPENHAGEN, Denmark; August 7, 2025 •Epcoritamab in combination with rituximab and lenalidomide (R2) demonstrated statistically significant improvement in Overall Response Rate (ORR; 95.7%, p < 0.0001) and Progression- |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal execut |
|
| July 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JULY 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| July 16, 2025 |
Exhibit 99.1 Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025 Company Announcement •Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 million •Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 16, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldw |
|
| July 3, 2025 |
As filed with the U.S. Securities and Exchange Commission on July 3, 2025 As filed with the U.S. Securities and Exchange Commission on July 3, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FOR DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS GENMAB A/S (Exact name of issuer of deposited securities as specified in its charter) N/A (Translation |
|
| July 3, 2025 |
Exhibit (d) July 3, 2025 JPMorgan Chase Bank, N.A., as Depositary 383 Madison Avenue, Floor 11 New York, NY 10179 Re: Registration Statement on Form F-6 – American Depositary Shares evidenced by American Depositary Receipts for deposited ordinary shares of Genmab A/S Ladies and Gentlemen: We have acted as counsel to JPMorgan Chase Bank, N.A., as depositary (the “Depositary”), in connection with th |
|
| July 3, 2025 |
Exhibit (a) TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions 1 (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 2 (d) Beneficial Owner 2 (e) Commission 2 (f) Custodian 2 (g) Deliver, execute, issue et al. 2 (h) Delivery Order 2 (i) Deposited Securities 2 (j) Direct Registration System 3 (k) Holder |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 30, 2025 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for June 23 – 26 Issuer Date Time CET Quantity Price (DKK) Venue GENMAB A/S 23-Jun-2025 09:44:59 AM 5 1365.00 XCSE GENMAB A/S 23-Jun-2025 09:45:11 AM 3 1363.50 XCSE GENMAB A/S 23-Jun-2025 10:01:01 AM 1 1366.00 XCSE GENMAB A/S 23-Jun-2025 10:01:01 AM 4 1366.00 XCSE GENMAB A/S 23-Jun-2025 10:40:33 AM 5 1363.00 XCSE GENMAB A/S 23-Jun-2 |
|
| June 30, 2025 |
Exhibit 99.1 Completion of Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 30, 2025 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2025. On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted S |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 23, 2025 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for June 16 - 20, 2025 Issuer Date Time CET Quantity Price (DKK) Venue GENMAB A/S 16-Jun-2025 09:35:21 AM 5 1471.00 XCSE GENMAB A/S 16-Jun-2025 09:35:26 AM 5 1470.00 XCSE GENMAB A/S 16-Jun-2025 10:11:41 AM 6 1479.50 XCSE GENMAB A/S 16-Jun-2025 10:50:20 AM 5 1486.00 XCSE GENMAB A/S 16-Jun-2025 11:27:59 AM 6 1484.00 XCSE GENMAB A/S 16 |
|
| June 23, 2025 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 23, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 18, 2025 |
Articles of Association Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Exhibit 3.1 (English translation of Articles of Association) (June 17, 2025) Articles of Association Of Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) 2 Name, Registered Office, Objects and Group Language § 1. The name of the Company is Genmab A/S. § 2. The registered office of the Company shall be in the municipality of Copenhagen. § 3. The objects of the Company are to enga |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 17, 2025 |
Exhibit 99.1 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Ge |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 17, 2025 |
Exhibit 99.1 Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 32,117 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subsc |
|
| June 16, 2025 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for June 9-13, 2025 Issuer Date Time CET Quantity Price (DKK) Venue GENMAB A/S 10-Jun-2025 09:31:01 AM 5 1464.00 XCSE GENMAB A/S 10-Jun-2025 09:33:24 AM 4 1464.00 XCSE GENMAB A/S 10-Jun-2025 09:33:24 AM 1 1464.00 XCSE GENMAB A/S 10-Jun-2025 10:08:13 AM 5 1471.00 XCSE GENMAB A/S 10-Jun-2025 10:51:50 AM 7 1468.50 XCSE GENMAB A/S 10-Ju |
|
| June 16, 2025 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 16, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 16, 2025 |
Articles of Association Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Exhibit 3.1 (English translation of Articles of Association) (June 12, 2025) Articles of Association Of Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) 2 Name, Registered Office, Objects and Group Language § 1. The name of the Company is Genmab A/S. § 2. The registered office of the Company shall be in the municipality of Copenhagen. § 3. The objects of the Company are to enga |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 12, 2025 |
Exhibit 99.1 Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; June 12, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 3,320 restricted stock units and 3,636 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the o |
|
| June 10, 2025 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for June 2-6, 2025 Issuer Date Time CET Quantity Price (DKK) Venue GENMAB A/S 02-Jun-2025 10:00:42 AM 5 1432.50 XCSE GENMAB A/S 02-Jun-2025 10:00:42 AM 5 1431.50 XCSE GENMAB A/S 02-Jun-2025 10:35:18 AM 6 1422.00 XCSE GENMAB A/S 02-Jun-2025 11:15:59 AM 6 1417.00 XCSE GENMAB A/S 02-Jun-2025 12:04:44 PM 6 1420.00 XCSE GENMAB A/S 02-Jun |
|
| June 10, 2025 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 10, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 2, 2025 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 2, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 2, 2025 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for May 26 – 28, 2025 Issuer Date Time CET Quantity Price (DKK) Venue GENMAB A/S 26-May-2025 09:41:37 AM 5 1375.50 XCSE GENMAB A/S 26-May-2025 09:42:03 AM 5 1374.00 XCSE GENMAB A/S 26-May-2025 10:08:10 AM 6 1381.00 XCSE GENMAB A/S 26-May-2025 10:50:37 AM 5 1379.50 XCSE GENMAB A/S 26-May-2025 11:37:40 AM 6 1377.00 XCSE GENMAB A/S 26- |
|
| May 27, 2025 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for May 19 – 23, 2025 Issuer Date Time CET Quantity Price (DKK) Venue GENMAB A/S 19-May-2025 10:26:31 AM 34 1313.00 XCSE GENMAB A/S 19-May-2025 10:26:31 AM 49 1313.00 XCSE GENMAB A/S 19-May-2025 10:30:14 AM 81 1317.00 XCSE GENMAB A/S 19-May-2025 10:30:33 AM 70 1316.00 XCSE GENMAB A/S 19-May-2025 10:32:50 AM 37 1316.00 XCSE GENMAB A/ |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive |
|
| May 27, 2025 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 26, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive |
|
| May 21, 2025 |
Articles of Association Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Exhibit 3.1 (English translation of Articles of Association) (May 20, 2025) Articles of Association Of Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) 2 Name, Registered Office, Objects and Group Language § 1. The name of the Company is Genmab A/S. § 2. The registered office of the Company shall be in the municipality of Copenhagen. § 3. The objects of the Company are to engag |
|
| May 20, 2025 |
Exhibit 99.1 Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; May 20, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 1,746 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscri |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive |
|
| May 19, 2025 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement Company Announcement COPENHAGEN, Denmark; May 19, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back pr |
|
| May 19, 2025 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for May 12 – May 16, 2025 Issuer Date Time CET Quantity Price (DKK) Venue GENMAB A/S 12-May-2025 09:30:02 AM 75 1211.00 XCSE GENMAB A/S 12-May-2025 09:30:11 AM 75 1214.50 TQEX GENMAB A/S 12-May-2025 09:30:11 AM 1 1214.50 TQEX GENMAB A/S 12-May-2025 09:30:11 AM 78 1214.50 CEUX GENMAB A/S 12-May-2025 09:30:11 AM 76 1214.50 AQEU GENMAB |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive |
|
| May 12, 2025 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for May 5-9, 2025 Issuer Date Time CET Quantity Price (DKK) Venue GENMAB A/S 05-May-2025 09:32:27 AM 85 1431.50 XCSE GENMAB A/S 05-May-2025 09:36:46 AM 54 1433.50 XCSE GENMAB A/S 05-May-2025 09:40:53 AM 41 1434.50 XCSE GENMAB A/S 05-May-2025 09:42:03 AM 31 1433.50 XCSE GENMAB A/S 05-May-2025 09:42:03 AM 4 1432.50 XCSE GENMAB A/S 05- |
|
| May 12, 2025 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 12, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive |
|
| May 8, 2025 |
99.1 Genmab Announces Financial Results for the First Quarter of 2025 May 8, 2025 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025 Highlights •EPKINLY® (epcoritamab) approved by the Japan Ministry of Health, Labour and Welfare (MHLW) for additional indication as a treatment for relapsed or refractory follicular lymphoma (FL) •Rinatabart sesutecan (Rina-S®) continues t |
|
| May 5, 2025 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 5, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to b |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive |
|
| May 5, 2025 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for April 28 – May 2, 2025 Issuer Date Time CET Quantity Price (DKK) Venue GENMAB A/S 28-Apr-2025 09:37:54 AM 91 1354.50 XCSE GENMAB A/S 28-Apr-2025 09:40:18 AM 83 1353.50 XCSE GENMAB A/S 28-Apr-2025 09:40:59 AM 95 1352.50 XCSE GENMAB A/S 28-Apr-2025 09:42:00 AM 44 1350.50 XCSE GENMAB A/S 28-Apr-2025 09:45:52 AM 31 1349.50 XCSE GENM |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive |
|
| May 2, 2025 |
Exhibit 99.1 Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) Company Announcement •Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE® FL |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| April 28, 2025 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification April 21 - 25, 2025 Issuer Date Time CET Quantity Price (DKK) Venue GENMAB A/S 22-Apr-2025 10:49:10 AM 83 1289.50 XCSE GENMAB A/S 22-Apr-2025 10:51:27 AM 37 1289.50 XCSE GENMAB A/S 22-Apr-2025 10:51:44 AM 79 1288.50 XCSE GENMAB A/S 22-Apr-2025 10:52:59 AM 27 1291.00 XCSE GENMAB A/S 22-Apr-2025 10:53:20 AM 26 1290.00 XCSE GENMAB A/S |
|
| April 28, 2025 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; April 28, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected t |
|
| April 22, 2025 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; April 22, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected t |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| April 22, 2025 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for April 14 – April 18, 2025 Issuer Date Time CET Quantity Price (DKK) Venue GENMAB A/S 14-Apr-2025 9:55:18 AM 78 1259.50 XCSE GENMAB A/S 14-Apr-2025 9:55:30 AM 82 1259.00 CEUX GENMAB A/S 14-Apr-2025 9:55:32 AM 86 1258.50 XCSE GENMAB A/S 14-Apr-2025 9:56:01 AM 76 1258.00 TQEX GENMAB A/S 14-Apr-2025 9:56:14 AM 74 1258.00 AQEU GENMAB |
|
| April 15, 2025 |
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025 Exhibit 99.1 Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025 Company Announcement ● Net sales of DARZALEX® in the first quarter of 2025 totaled USD 3,237 million ● Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; April 15, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that world |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| April 14, 2025 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; April 14, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected t |
|
| April 14, 2025 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for April 7 – April 9, 2025 Issuer Date Time CET Quantity Price (DKK) Venue GENMAB A/S 07-Apr-2025 09:35:27 AM 42 1177.00 XCSE GENMAB A/S 07-Apr-2025 09:35:27 AM 32 1177.00 XCSE GENMAB A/S 07-Apr-2025 09:35:27 AM 80 1177.00 AQEU GENMAB A/S 07-Apr-2025 09:35:27 AM 73 1177.00 CEUX GENMAB A/S 07-Apr-2025 09:35:33 AM 54 1177.00 XCSE GEN |
|
| April 14, 2025 |
Exhibit 99.1(b) APPENDIX Share buy-back programme - Specification for April 10 – April 11, 2025 GENMAB A/S 10-Apr-2025 09:37:32 AM 1 1260.50 XCSE GENMAB A/S 10-Apr-2025 09:37:32 AM 87 1260.50 XCSE GENMAB A/S 10-Apr-2025 09:37:32 AM 78 1259.50 XCSE GENMAB A/S 10-Apr-2025 09:37:32 AM 86 1260.50 CEUX GENMAB A/S 10-Apr-2025 09:37:32 AM 74 1259.50 CEUX GENMAB A/S 10-Apr-2025 09:37:32 AM 76 1260.00 AQEU |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| April 10, 2025 |
Articles of Association Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Exhibit 3.1 (English translation of Articles of Association) (March 12, 2025) - III Articles of Association Of Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Page 2 of 47 Name, Registered Office, Objects and Group Language § 1. The name of the Company is Genmab A/S. § 2. The registered office of the Company shall be in the municipality of Copenhagen. § 3. The objects of the C |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| April 10, 2025 |
Genmab A/S Share Capital Reduction Exhibit 99.1 Genmab A/S Share Capital Reduction Company Announcement COPENHAGEN, Denmark; April 10, 2025 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S’ Annual General Meeting on March 12, 2025, it was decided to reduce the Company’s share capital with nominally DKK 2,076,853 by cancellation of 2,076,853 of the Company’s holding of shares with a nominal value of DKK 1 each. The share capital reduction |
|
| April 7, 2025 |
Exhibit 99.1 Transactions In Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; April 7, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| April 7, 2025 |
Exhibit 99.1(b) APPENDIX Share buy-back programme - Specification for April 3 – April 4, 2025 Issuer Date Time CET Quantity Price (DKK) Venue GENMAB A/S 03-Apr-2025 09:26:59 AM 71 1281.50 CEUX GENMAB A/S 03-Apr-2025 09:26:59 AM 8 1281.50 CEUX GENMAB A/S 03-Apr-2025 09:27:15 AM 21 1282.00 AQEU GENMAB A/S 03-Apr-2025 09:27:15 AM 55 1282.00 AQEU GENMAB A/S 03-Apr-2025 09:27:19 AM 19 1281.00 XCSE GENM |
|
| April 7, 2025 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for March 31 – April 2, 2025 Issuer Date Time CET Quantity Price (DKK) Venue GENMAB A/S 31-Mar-2025 09:42:24 AM 61 1345.50 TQEX GENMAB A/S 31-Mar-2025 09:42:24 AM 73 1345.50 CEUX GENMAB A/S 31-Mar-2025 09:42:25 AM 68 1345.50 XCSE GENMAB A/S 31-Mar-2025 09:42:25 AM 72 1345.00 AQEU GENMAB A/S 31-Mar-2025 09:42:44 AM 64 1344.50 XCSE GE |
|
| April 1, 2025 |
Exhibit 99.1 Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons Company Announcement COPENHAGEN, Denmark; April 1, 2025 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Ge |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| March 31, 2025 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for March 26 – March 28, 2025 Issuer Date Time CET Quantity Price (DKK) Venue GENMAB A/S 26-Mar-25 9:30:18 AM 70 1337.00 XCSE GENMAB A/S 26-Mar-25 9:30:42 AM 42 1338.00 XCSE GENMAB A/S 26-Mar-25 9:30:42 AM 67 1338.00 CEUX GENMAB A/S 26-Mar-25 9:32:04 AM 56 1338.50 XCSE GENMAB A/S 26-Mar-25 9:32:04 AM 68 1339.50 XCSE GENMAB A/S 26-Ma |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| March 31, 2025 |
Exhibit 99.1 Transactions in connection with share buy-back program Company Announcement COPENHAGEN, Denmark; March 31, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected t |
|
| March 25, 2025 |
Genmab Announces Initiation of Share Buy-Back Program Exhibit 99.1 Genmab Announces Initiation of Share Buy-Back Program Company Announcement ● Repurchase of up to 2.2 million shares with a maximum aggregate total value of DKK 4.0 billion ● Reduce the capital of Genmab and honor our commitments under the Restricted Stock Unit program ● Completion expected no later than July 10, 2025 COPENHAGEN, Denmark; March 25, 2025 – Genmab A/S (Nasdaq: GMAB) anno |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| March 24, 2025 |
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. Exhibit 99.1 Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. Company Announcement ● AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle) ● Genmab categorically refutes allegations and will vigorously defend the company COPENHAGEN, Denmark; March 22, 2025 – Genmab A/S (Nasdaq: GMAB) announce |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| March 20, 2025 |
Articles of Association Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) EX-3.1 2 tmb-20250320xex3d1.htm EX-3.1 Exhibit 3.1 (English translation of Articles of Association) (March 12, 2025) - II Articles of Association Of Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Page 2 of 47 Name, Registered Office, Objects and Group Language § 1. The name of the Company is Genmab A/S. § 2. The registered office of the Company shall be in the municipality of |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| March 12, 2025 |
Passing of Genmab A/S’ Annual General Meeting Exhibit 99.1 Passing of Genmab A/S’ Annual General Meeting Company Announcement ● At Genmab A/S’ Annual General Meeting held today March 12, 2025, the Annual Report for 2024 was approved ● Discharge was given to the Board of Directors and the Executive Management and the year’s profit was carried forward ● The 2024 Compensation Report was approved ● Six members of the Board of Directors were re-el |
|
| March 12, 2025 |
Exhibit 99.1 Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 12, 2025, the Company’s Board of Directors met to constitute itself. Ms. Deirdre |
|
| March 12, 2025 |
Exhibit 99.2 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in G |
|
| March 10, 2025 |
Genmab Announces Johnson & Johnson Decision Regarding HexaBody Exhibit 99.1 Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38 Company Announcement ● Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 ● Genmab will not pursue further clinical development of HexaBody-CD38 ● Data validates clinical potential of the HexaBody platform ● Genmab |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| March 6, 2025 |
Articles of Association Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) (Unauthorized English translation) (February 28, 2025) Articles of Association of Genmab A/S (CVR-nr. |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| March 4, 2025 |
Exhibit 99.1 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; March 4, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Ge |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF FEBRUARY 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal exec |
|
| February 28, 2025 |
Exhibit 99.1 Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 614,676 restricted stock units to members of management and employees of the Company as well as the Company's subsidiaries and 517,191 warrants to |
|
| February 28, 2025 |
Exhibit 99.2 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made i |
|
| February 26, 2025 |
Articles of Association Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Exhibit 3.1 (English translation of Articles of Association) (February 25, 2025) Articles of Association Of Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Page 2 of 45 Name, Registered Office, Objects and Group Language § 1. The name of the Company is Genmab A/S. § 2. The registered office of the Company shall be in the municipality of Copenhagen. § 3. The objects of the Comp |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF FEBRUARY 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal exec |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF FEBRUARY 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal exec |
|
| February 25, 2025 |
Capital Increase in Genmab as a Result of Employee Warrant Exercise Exhibit 99.1 Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; February 25, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,058 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are s |
|
| February 13, 2025 |
Exhibit 99.1 Notice to Convene the Annual General Meeting of Genmab A/S Company Announcement ● Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025 COPENHAGEN, Denmark; February 13, 2025 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Wednesday, March 12, 2025, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, DK-1560 Copenhagen V, Denmark. The |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF FEBRUARY 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal exec |
|
| February 12, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-253519, 333-232693 and 333-262970) of Genmab A/S of our report dated February 14, 2024, except for the revisions in note 4.5, as to which the date is February 12, 2025 relating to the consolidated financial statements, which a |
|
| February 12, 2025 |
[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] Exhibit 11.1 INTERNAL RULES FOR THE MEMBERS OF THE BOARD OF DIRECTORS AND THE EXECUTIVE MANAGEMENT AND OTHER PERMANENT INSIDERS OF GENMAB A/S (CVR NO. 21032884) REGARDING THE PREVENTION OF INSIDER DEALING, TRADING WINDOWS, UNLAWFUL DISCLOSURE OF INSIDE INFORMATION, NOTIFICATION OF TRANSACTIONS AND GUIDELINES FOR THE COMPANY'S TRADE IN ITS OWN SECURITIES. 1. PURPOSES 1.1 The purposes of the followi |
|
| February 12, 2025 |
As filed with the Securities and Exchange Commission on February 12, 2025 As filed with the Securities and Exchange Commission on February 12, 2025 Registration No. |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ◻ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT |
|
| February 12, 2025 |
EXHIBIT 13.1 PRINCIPAL EXECUTIVE OFFICER CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Jan G. van de Winkel, President and Chief Executive Officer of Genmab A/S, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: (1) The Annual Report on F |
|
| February 12, 2025 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) GENMAB A/S (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title(1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, DKK 1 nominal value per share (“Ordinary Shares”)(1)(2) reserved for issuance under the Genmab A/S 2021 Restricted Stock Units Program Rule 457(c) and Rule 457(h) 800,000 $193. |
|
| February 12, 2025 |
EXHIBIT 13.2 PRINCIPAL FINANCIAL OFFICER CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Anthony Pagano, Executive Vice President and Chief Financial Officer of Genmab A/S, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: (1) The |
|
| February 12, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement Nos. 333-232693, 333-253519, 333-262970 and 333-277273 on Form S-8 of our reports dated February 12, 2025, relating to the financial statements of Genmab A/S and the effectiveness of Genmab A/S’ internal control over financial reporting appearing in this Annu |
|
| February 12, 2025 |
Exhibit 15.4 February 12, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Genmab A/S (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to item 16F of Form 20-F of Genmab A/S dated February 12, 2025. We agree with the statements concerning our Firm contained the |
|
| February 12, 2025 |
CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER EXHIBIT 12.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER I, Jan G. van de Winkel, certify that: 1. I have reviewed this annual report on Form 20-F of Genmab A/S; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were mad |
|
| February 12, 2025 |
Exhibit 99.1a 2024 Annual Report CVR No. 21 02 38 84 Genmab A/S Carl Jacobsens Vej 30 2500 Valby Denmark Leading Antibody Science for Better Futures Management’s Review 4 Our 2030 Vision 5 Chair’s Statement 7 Letter from the CEO 9 2024 at a Glance 10 Consolidated Key Figures 11 2025 Outlook 12 Our Strategy 13 Who We Are 14 Business Model 15 Value Chain 17 Research and Development Capabilities 19 B |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF FEBRUARY 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal exec |
|
| February 12, 2025 |
* 2020 Operating Profit impacted by one-time AbbVie upfront payment. Exhibit 99.1 GENMAB 2024 ANNUAL REPORT Table of Contents GENMAB 2024 ANNUAL REPORT Management’s Review Our 2030 Vision 1 Chair’s Statement 3 Letter from the CEO 4 2024 at a Glance 5 Consolidated Key Figures 8 2025 Outlook 10 Our Strategy 12 Who We Are 14 Business Model 15 Value Chain 15 Research and Development Capabilities 18 Bringing Our Own Innovative Medicines to Patients 19 Antibody Discovery |
|
| February 12, 2025 |
CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER EXHIBIT 12.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER I, Anthony Pagano, certify that: 1. I have reviewed this annual report on Form 20-F of Genmab A/S; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not |
|
| February 12, 2025 |
Exhibit 11.2 INTERNAL RULES FOR THE EMPLOYEES OF GENMAB A/S (CVR NO. 21032884) AND ITS DIRECTLY AND INDIRECTLY OWNED SUBSIDIARIES REGARDING THE PREVENTION OF INSIDER DEALING, OPEN TRADING WINDOWS AND UNLAWFUL DISCLOSURE OF INSIDE INFORMATION 1. PURPOSES 1.1 The purposes of the following rules are to prevent the employees of Genmab A/S (the "Company") and its directly and indirectly owned subsidiar |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JANUARY 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal execu |
|
| January 29, 2025 |
Articles of Association Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Exhibit 3.1 (English translation of Articles of Association) (January 29, 2025) Articles of Association Of Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Page 2 of 46 Name, Registered Office, Objects and Group Language § 1. The name of the Company is Genmab A/S. § 2. The registered office of the Company shall be in the municipality of Copenhagen. § 3. The objects of the Compa |
|
| January 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JANUARY 2025 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal execu |
|
| January 23, 2025 |
Grant of Restricted Stock Units and Warrants to Employees in Genmab EX-99.1 2 tmb-20250123xex99d1.htm EX-99.1 Exhibit 99.1 Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; January 23, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 4,903 restricted stock units and 5,289 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awar |
|
| January 22, 2025 |
Genmab Announces Net Sales of DARZALEX Exhibit 99.1 Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024 Company Announcement ● Net sales of DARZALEX® in 2024 totaled USD 11,670 million ● Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; January 22, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® ( |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JANUARY 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal execu |
|
| December 4, 2024 |
Articles of Association Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Exhibit 3.1 (English translation of Articles of Association) (December 4, 2024) Articles of Association Of Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Page 2 of 45 Name, Registered Office, Objects and Group Language § 1. The name of the Company is Genmab A/S. § 2. The registered office of the Company shall be in the municipality of Copenhagen. § 3. The objects of the Compa |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF DECEMBER 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal exec |
|
| December 3, 2024 |
Exhibit 99.1 Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons Company Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in |
|
| December 3, 2024 |
Capital Increase in Genmab as a Result of Employee Warrant Exercise Exhibit 99.1 Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,355 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are su |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF DECEMBER 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal exec |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF DECEMBER 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal exec |
|
| November 27, 2024 |
Articles of Association Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Exhibit 3.1 (English translation of Articles of Association) (November 21, 2024) Articles of Association Of Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Page 2 of 45 Name, Registered Office, Objects and Group Language § 1. The name of the Company is Genmab A/S. § 2. The registered office of the Company shall be in the municipality of Copenhagen. § 3. The objects of the Comp |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal exec |
|
| November 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal exec |
|
| November 21, 2024 |
Grant of Restricted Stock Units and Warrants to Employees in Genmab Exhibit 99.1 Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; November 21, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 10,273 restricted stock units and 10,853 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner wi |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal exec |
|
| November 6, 2024 |
Exhibit 99.1 Genmab Announces Financial Results for the First Nine Months of 2024 November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights ● European Commission (EC) granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal execu |
|
| October 15, 2024 |
Genmab Announces Net Sales of DARZALEX Exhibit 99.1 Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024 Company Announcement ● Net sales of DARZALEX® in the third quarter of 2024 totaled USD 3,016 million ● Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; October 15, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DA |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal execu |
|
| October 4, 2024 |
Major shareholder announcement for Genmab A/S Exhibit 99.1 Major shareholder announcement for Genmab A/S Company Announcement ● Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 4, 2024 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Baillie Gifford & Co has informed us that, as of October 3, 2024, Baillie Gifford & Co held the voting rights to 3,301,530 share |
|
| October 1, 2024 |
Articles of Association Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Exhibit 3.1 (English translation of Articles of Association) (September 26, 2024) Articles of Association Of Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Page 2 of 45 Name, Registered Office, Objects and Group Language § 1. The name of the Company is Genmab A/S. § 2. The registered office of the Company shall be in the municipality of Copenhagen. § 3. The objects of the Com |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal execu |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF SEPTEMBER 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal exe |
|
| September 26, 2024 |
Grant of Restricted Stock Units and Warrants to Employees in Genmab Exhibit 99.1 Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; September 26, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 23,954 restricted stock units and 13,915 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner w |
|
| September 11, 2024 |
Articles of Association Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Exhibit 3.1 (English translation of Articles of Association) (September 10, 2024) Articles of Association Of Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Page 2 of 45 Name, Registered Office, Objects and Group Language § 1. The name of the Company is Genmab A/S. § 2. The registered office of the Company shall be in the municipality of Copenhagen. § 3. The objects of the Com |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF SEPTEMBER 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal exe |
|
| September 10, 2024 |
Capital Increase in Genmab as a Result of Employee Warrant Exercise Exhibit 99.1 Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; September 10, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 11,729 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF SEPTEMBER 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal exe |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal execut |
|
| August 21, 2024 |
Exhibit 99.1 TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma Company Announcement ● TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLB |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal execut |
|
| August 14, 2024 |
Articles of Association Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Exhibit 3.1 (English translation of Articles of Association) (August 14, 2024) Articles of Association Of Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Page 2 of 45 Name, Registered Office, Objects and Group Language § 1. The name of the Company is Genmab A/S. § 2. The registered office of the Company shall be in the municipality of Copenhagen. § 3. The objects of the Compan |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal execut |
|
| August 13, 2024 |
Capital Increase in Genmab as a Result of Employee Warrant Exercise Exhibit 99.1 Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,193 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are sub |
|
| August 13, 2024 |
Exhibit 99.2 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in |
|
| August 8, 2024 |
ex. Acquisition and Integration related charges Exhibit 99.1 Genmab Announces Financial Results for the First Half of 2024 August 8, 2024 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2024 Highlights ● Completed acquisition of ProfoundBio Inc (ProfoundBio), granting Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug co |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal execut |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal execut |
|
| August 8, 2024 |
ex. Acquisition and Integration related charges Exhibit 99.1 Genmab Updates 2024 Financial Guidance Company Announcement ● Genmab updates its 2024 financial guidance ● Increase in revenue driven by higher royalties and reimbursement revenue ● Increase in operating profit excluding acquisition and integration charges, driven by higher revenue and focused investments COPENHAGEN, Denmark; August 8, 2024 – Genmab A/S (Nasdaq: GMAB) announced today |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal execut |
|
| August 5, 2024 |
Genmab Takes Full Control of Acasunlimab Development Program Exhibit 99.1 Genmab Takes Full Control of Acasunlimab Development Program Company Announcement ● Genmab to assume sole responsibility for the continued development and potential commercialization of acasunlimab ● BioNTech has opted not to participate in the further development of the acasunlimab program under the parties’ existing collaboration agreement ● The overall collaboration between the com |
|
| July 17, 2024 |
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024 Exhibit 99.1 Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024 Company Announcement ● Net sales of DARZALEX® in the second quarter of 2024 totaled USD 2,878 million ● Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; July 17, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DAR |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JULY 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 28, 2024 |
Exhibit 99.1 Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma Company Announcement ● Positive CHMP opinion based on results from the Phase 1/2 EPCORE® NHL-1 study ● FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases ● If approved, epcoritamab (TEPKINLY®) would beco |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 27, 2024 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for June 24 – June 26, 2024 Issuer Date Time CEST Price (DKK) Quantity Venue Genmab A/S 24/06/2024 9:07:21 AM 1,804.0000 70 XCSE Genmab A/S 24/06/2024 9:07:21 AM 1,804.0000 33 XCSE Genmab A/S 24/06/2024 9:07:21 AM 1,804.0000 33 XCSE Genmab A/S 24/06/2024 9:07:21 AM 1,804.0000 70 XCSE Genmab A/S 24/06/2024 9:07:21 AM 1,804.0000 33 XC |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 27, 2024 |
Exhibit 99.1 Completion of Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 27, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2024. On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program was expected to be completed |
|
| June 27, 2024 |
Exhibit 99.1 EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Company Announcement ● Approval based on results from Phase 1/2 EPCORE® NHL-1 study, which demonstrated durable, clinically meaningful treatment responses in patients with challenging-to-treat R/R FL ● EPKINLY offers an off-the-shelf, T-cell engaging treatment optio |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 24, 2024 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 24, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions |
|
| June 24, 2024 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for June 17 – June 21, 2024 Issuer Date Time CEST Price (DKK) Quantity Venue Genmab A/S 17/06/2024 9:03:30 AM 1,826.0000 22 XCSE Genmab A/S 17/06/2024 9:03:30 AM 1,826.0000 24 XCSE Genmab A/S 17/06/2024 9:03:30 AM 1,826.0000 22 XCSE Genmab A/S 17/06/2024 9:03:30 AM 1,826.0000 24 XCSE Genmab A/S 17/06/2024 9:03:30 AM 1,826.0000 53 XC |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 20, 2024 |
Articles of Association Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Exhibit 3.1 (English translation of Articles of Association) (June 18, 2024) Articles of Association Of Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Page 2 of 45 Name, Registered Office, Objects and Group Language § 1. The name of the Company is Genmab A/S. § 2. The registered office of the Company shall be in the municipality of Copenhagen. § 3. The objects of the Company |
|
| June 18, 2024 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for June 10 – June 14, 2024 Issuer Date Time CEST Price (DKK) Quantity Venue Genmab A/S 10/06/2024 9:10:44 AM 1,915.0000 16 AQEU Genmab A/S 10/06/2024 9:10:44 AM 1,915.0000 10 AQEU Genmab A/S 10/06/2024 9:10:44 AM 1,915.0000 39 AQEU Genmab A/S 10/06/2024 9:10:44 AM 1,914.5000 32 XCSE Genmab A/S 10/06/2024 9:10:44 AM 1,914.5000 34 XC |
|
| June 18, 2024 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 18, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 18, 2024 |
Capital Increase in Genmab as a Result of Employee Warrant Exercise Exhibit 99.1 Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; June 18, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,986 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscr |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 17, 2024 |
Articles of Association Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Exhibit 3.1 (English translation of Articles of Association) (June12, 2024) Articles of Association Of Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Page 2 of 45 Name, Registered Office, Objects and Group Language § 1. The name of the Company is Genmab A/S. § 2. The registered office of the Company shall be in the municipality of Copenhagen. § 3. The objects of the Company a |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 12, 2024 |
Grant of Restricted Stock Units and Warrants to Employees in Genmab Exhibit 99.1 Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; June 12, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 15,711 restricted stock units and 16,052 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 11, 2024 |
Exhibit 99.1 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement COPENHAGEN, Denmark; June 11, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Ge |
|
| June 10, 2024 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 10, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 10, 2024 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for June 3 – June 7, 2024 Issuer Date Time CEST Price (DKK) Quantity Venue Genmab A/S 03/06/2024 3:00:28 PM 1,948.5000 35 CEUX Genmab A/S 03/06/2024 3:04:13 PM 1,944.5000 19 TQEX Genmab A/S 03/06/2024 3:04:13 PM 1,944.5000 18 TQEX Genmab A/S 03/06/2024 3:04:13 PM 1,944.0000 38 XCSE Genmab A/S 03/06/2024 3:18:58 PM 1,950.0000 34 XCSE |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executiv |
|
| June 3, 2024 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for May 27 – May 29, 2024 Issuer Date Time CEST Price (DKK) Quantity Venue Genmab A/S 27/05/2024 09:01:38 1,914.5000 7 XCSE Genmab A/S 27/05/2024 09:01:38 1,914.5000 16 XCSE Genmab A/S 27/05/2024 09:02:46 1,915.0000 7 XCSE Genmab A/S 27/05/2024 09:02:46 1,915.0000 45 XCSE Genmab A/S 27/05/2024 09:02:46 1,915.0000 8 CEUX Genmab A/S 2 |
|
| June 3, 2024 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for May 30 – May 31, 2024 Issuer Date Time CEST Price (DKK) Quantity Venue Genmab A/S 30/05/2024 09:02:03 1,922.0000 24 XCSE Genmab A/S 30/05/2024 09:02:03 1,922.0000 24 XCSE Genmab A/S 30/05/2024 09:02:03 1,922.0000 18 XCSE Genmab A/S 30/05/2024 09:02:03 1,922.0000 22 CEUX Genmab A/S 30/05/2024 09:02:03 1,922.0000 22 CEUX Genmab A/ |
|
| June 3, 2024 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; June 3, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions w |
|
| May 28, 2024 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 27, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions w |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive |
|
| May 28, 2024 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for May 20 – May 24, 2024 Issuer Date Time CEST Price (DKK) Quantity Venue Genmab A/S 21/05/2024 09:28:05 2,026.0000 39 XCSE Genmab A/S 21/05/2024 09:28:05 2,025.0000 38 CEUX Genmab A/S 21/05/2024 09:28:05 2,025.0000 2 CEUX Genmab A/S 21/05/2024 09:37:02 2,020.0000 6 XCSE Genmab A/S 21/05/2024 09:37:02 2,020.0000 29 XCSE Genmab A/S |
|
| May 21, 2024 |
zzz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal execu |
|
| May 21, 2024 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 21, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions w |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive |
|
| May 21, 2024 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for May 13 – May 17, 2024 Issuer Date Time CEST Price (DKK) Quantity Venue GENMAB A/S 13/05/2024 09:00:01 2,002.00 53 XCSE GENMAB A/S 13/05/2024 09:00:01 2,002.00 53 XCSE GENMAB A/S 13/05/2024 09:00:01 2,002.00 9 XCSE GENMAB A/S 13/05/2024 09:01:42 2,001.00 36 XCSE GENMAB A/S 13/05/2024 09:02:02 2,000.00 39 XCSE GENMAB A/S 13/05/202 |
|
| May 21, 2024 |
Genmab Completes Acquisition of ProfoundBio Exhibit 99.1 Genmab Completes Acquisition of ProfoundBio Company Announcement ● Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash ● Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugate technology platforms COPENHAGEN, Denmark; May 21, 2024 – Genmab A |
|
| May 13, 2024 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for May 6 – May 10, 2024 Issuer Date Time CEST Price (DKK) Quantity Venue GENMAB A/S 05/07/2024 14:23:31 1,998.00 35 CEUX GENMAB A/S 05/08/2024 9:01:56 2,002.00 23 TQEX GENMAB A/S 05/08/2024 9:01:56 2,002.00 14 TQEX GENMAB A/S 05/08/2024 10:21:50 2,016.00 13 CEUX GENMAB A/S 05/08/2024 10:21:50 2,016.00 6 CEUX GENMAB A/S 05/08/2024 1 |
|
| May 13, 2024 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 13, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions w |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive |
|
| May 8, 2024 |
Articles of Association Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Exhibit 3.1 (English translation of Articles of Association) (May 7, 2024) Articles of Association Of Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Page 2 of 45 Name, Registered Office, Objects and Group Language § 1. The name of the Company is Genmab A/S. § 2. The registered office of the Company shall be in the municipality of Copenhagen. § 3. The objects of the Company ar |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive |
|
| May 7, 2024 |
Capital Increase in Genmab as a Result of Employee Warrant Exercise Exhibit 99.1 Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; May 7, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,959 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscrib |
|
| May 6, 2024 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 6, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions we |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive |
|
| May 6, 2024 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for April 29 – May 3, 2024 Issuer Date Time CEST Price (DKK) Quantity Venue Genmab A/S 29/04/2024 9:00:03 AM 1,959.00 45 XCSE Genmab A/S 29/04/2024 9:00:03 AM 1,959.00 27 XCSE Genmab A/S 29/04/2024 9:00:03 AM 1,959.00 12 XCSE Genmab A/S 29/04/2024 9:00:05 AM 1,959.00 4 XCSE Genmab A/S 29/04/2024 9:00:05 AM 1,959.00 3 XCSE Genmab A/S |
|
| May 2, 2024 |
Exhibit 99.1 Genmab Announces Financial Results for the First Quarter of 2024 May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights ● The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY® (epcoritamab-bysp) for the treatment of adult patients with relapsed or re |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| April 30, 2024 |
(tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer Exhibit 99.1 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer Company Announcement ● Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapy ● TIVDAK is the first antibody-drug conjugate in this patient population to have positive overall survival data COPENHAGEN, Denmark; Apri |
|
| April 29, 2024 |
Exhibit 99.1 Transactions in Connection with Share Buy-Back Program Company Announcement COPENHAGEN, Denmark; April 29, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions |
|
| April 29, 2024 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for April 22 – 26, 2024 Issuer Date Time CEST Price (DKK) Quantity Venue GENMAB A/S 22/04/2024 9:03:08 AM 2,011.00 33 XCSE GENMAB A/S 22/04/2024 9:05:55 AM 2,014.00 13 XCSE GENMAB A/S 22/04/2024 9:05:55 AM 2,014.00 112 XCSE GENMAB A/S 22/04/2024 9:05:55 AM 2,014.00 16 AQEU GENMAB A/S 22/04/2024 9:05:55 AM 2,014.00 89 CEUX GENMAB A/S |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| April 22, 2024 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for April15, – April 19, 2024 Issuer Date Time CEST Price (DKK) Quantity Venue GENMAB A/S 15/04/2024 9:01:58 AM 2,089.00 23 XCSE GENMAB A/S 15/04/2024 9:01:58 AM 2,089.00 23 XCSE GENMAB A/S 15/04/2024 9:01:58 AM 2,089.00 16 XCSE GENMAB A/S 15/04/2024 9:01:58 AM 2,089.00 23 XCSE GENMAB A/S 15/04/2024 9:01:58 AM 2,089.00 9 XCSE GENMAB |
|
| April 22, 2024 |
Transactions in Connection with Share Buy-back Program Genmab Exhibit 99.1 Transactions in Connection with Share Buy-back Program Genmab Company Announcement COPENHAGEN, Denmark; April 22, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following trans |
|
| April 16, 2024 |
Genmab Announces Net Sales of DARZALEX Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024 Company Announcement ● Net sales of DARZALEX® in the first quarter of 2024 totaled USD 2,692 million ● Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| April 15, 2024 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; April 15, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions |
|
| April 15, 2024 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for April 8 – April 12, 2024 Volume Price Venue Date Time CEST 21 2,060.00 XCSE 08/04/2024 09:02:14 21 2,060.00 XCSE 08/04/2024 09:02:14 54 2,060.00 XCSE 08/04/2024 09:02:14 24 2,059.00 XCSE 08/04/2024 09:02:14 18 2,059.00 XCSE 08/04/2024 09:02:14 21 2,060.00 XCSE 08/04/2024 09:02:14 21 2,060.00 XCSE 08/04/2024 09:02:14 21 2,060.00 |
|
| April 8, 2024 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for April 1 – April 5, 2024 Volume Price Venue Time CEST 4 2,105.00 TQEX 02/04/2024 1:00:00 3 2,107.00 AQEU 02/04/2024 1:00:00 18 2,107.00 CEUX 02/04/2024 1:00:00 4 2,107.00 TQEX 02/04/2024 1:00:00 3 2,107.00 AQEU 02/04/2024 1:00:00 3 2,107.00 AQEU 02/04/2024 1:00:00 18 2,107.00 CEUX 02/04/2024 1:00:00 18 2,107.00 CEUX 02/04/2024 1: |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| April 8, 2024 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; April 8, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| April 3, 2024 |
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio Exhibit 99.1 Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio Company Announcement ● Genmab to acquire ProfoundBio for USD 1.8 billion in cash ● Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugate (ADC) technology platforms ● Rina-S is |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| April 2, 2024 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; April 2, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions |
|
| April 2, 2024 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for March 25 – March 29, 2024 Volume Price Venue Time CET 13 2,054.0000 XCSE 25/03/2024 09:00:13 42 2,054.0000 CEUX 25/03/2024 09:00:13 74 2,054.0000 XCSE 25/03/2024 09:00:13 42 2,054.0000 CEUX 25/03/2024 09:00:13 1 2,054.0000 CEUX 25/03/2024 09:00:13 23 2,064.0000 XCSE 25/03/2024 09:05:34 23 2,064.0000 XCSE 25/03/2024 09:05:34 23 2 |
|
| March 25, 2024 |
Exhibit 99.1 Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; March 25, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions |
|
| March 25, 2024 |
Exhibit 99.1(a) APPENDIX Share buyback program - Specification for March 18-22, 2024 Volume Price Venue Time CET 20 2065.00 XCSE 18/03/2024 09:02:21 29 2065.00 XCSE 18/03/2024 09:02:21 29 2065.00 XCSE 18/03/2024 09:02:21 29 2065.00 XCSE 18/03/2024 09:02:21 3 2064.00 AQEU 18/03/2024 09:02:36 3 2064.00 AQEU 18/03/2024 09:02:36 3 2064.00 AQEU 18/03/2024 09:02:36 3 2064.00 AQEU 18/03/2024 09:02:36 3 2 |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| March 21, 2024 |
Articles of Association Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Exhibit 3.1 (English translation of Articles of Association) (March 13, 2024 - II) Articles of Association Of Genmab A/S (CVR-nr. 21023884 Formerly A/S registration no.: 248.498) Page 2 of 61 Name, Registered Office, Objects and Group Language § 1. The name of the Company is Genmab A/S. § 2. The registered office of the Company shall be in the municipality of Copenhagen. § 3. The objects of the Co |
|
| March 18, 2024 |
Completion of share buy-back program Exhibit 99.1 Completion of share buy-back program Company Announcement COPENHAGEN, Denmark; March 18, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 15, 2024 On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program. The share buy-back program was expect |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| March 18, 2024 |
Exhibit 99.1(a) APPENDIX Share buy-back programme - Specification for March 11 – March 15, 2024 Volume Price Venue Time CET 13 2071 XCSE 20240311 9:00:28.336000 13 2066 XCSE 20240311 9:00:30.390000 13 2064 XCSE 20240311 9:00:46.133000 13 2061 XCSE 20240311 9:01:04.163000 13 2064 XCSE 20240311 9:01:42.887000 14 2069 XCSE 20240311 9:02:15.678000 13 2069 XCSE 20240311 9:02:23.489000 13 2068 XCSE 2024 |
|
| March 15, 2024 |
Genmab Announces Initiation of Share Buy-Back Program Exhibit 99.1 Genmab Announces Initiation of Share Buy-Back Program Company Announcement ● Repurchase of up to DKK 3.5 billion worth of shares ● Completion expected no later than December 16, 2024 COPENHAGEN, Denmark; March 15, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that it is initiating a share buy-back program. The share buy-back program will be undertaken on the terms set out below and |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executi |
|
| March 13, 2024 |
Exhibit 99.1 Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; March 13, 2024 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 13, 2024, the Company’s Board of Directors met to constitute itself. Ms. Deirdre |
